恒瑞医药
(600276)
| 流通市值：2752.54亿 | | | 总市值：2863.95亿 |
| 流通股本：63.79亿 | | | 总股本：66.37亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 15,455,583,728.11 | 8,140,565,320.77 | 31,629,416,193.83 | 23,188,081,928.77 |
| 营业收入 | 15,455,583,728.11 | 8,140,565,320.77 | 31,629,416,193.83 | 23,188,081,928.77 |
| 二、营业总成本 | 11,313,140,405.95 | 5,642,928,613.81 | 23,093,097,613.72 | 16,915,649,809.76 |
| 营业成本 | 2,113,343,029.35 | 1,090,949,138.37 | 4,362,655,815.43 | 3,195,441,183.34 |
| 税金及附加 | 140,873,446.74 | 64,500,090.4 | 263,597,302.01 | 200,621,510.24 |
| 销售费用 | 4,340,919,075 | 2,196,612,842.37 | 9,106,426,024.5 | 6,780,484,625.55 |
| 管理费用 | 1,257,485,048.12 | 617,633,379.37 | 2,806,207,717.65 | 2,126,849,665.1 |
| 研发费用 | 3,492,911,607.38 | 1,650,624,680.45 | 6,961,155,413.23 | 4,945,318,580.23 |
| 财务费用 | -32,391,800.64 | 22,608,482.85 | -406,944,659.1 | -333,065,754.7 |
| 其中:利息费用 | 2,998,900.37 | 448,282.31 | 14,349,097.41 | 12,352,761.07 |
| 其中:利息收入 | 701,326,009.94 | 322,964,432.69 | 785,387,184.81 | 496,728,369.52 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 843,222,978.34 | 129,058,814.18 | 173,573,838.21 | 97,800,366.07 |
| 加:投资收益 | -63,147,682.14 | -61,353,119.01 | -80,184,824.51 | -40,823,206.64 |
| 资产处置收益 | 40,624,532.98 | 6,750,758.28 | 4,053,134.77 | 2,453,471.77 |
| 资产减值损失(新) | -18,334,072.43 | -14,313,440.94 | -86,914,039.97 | -13,599,294.17 |
| 信用减值损失(新) | 1,723,511.73 | -10,080,310.35 | -23,881,677.14 | -20,416,268.78 |
| 其他收益 | 141,209,898.57 | 59,744,118.88 | 467,037,830.52 | 326,665,251.85 |
| 四、营业利润 | 5,087,742,489.21 | 2,607,443,528 | 8,990,002,841.99 | 6,624,512,439.11 |
| 加:营业外收入 | 7,971,889.6 | 3,542,278.83 | 7,115,616.84 | 4,233,083.75 |
| 减:营业外支出 | 143,296,910.97 | 54,123,751.29 | 289,492,920.65 | 216,737,728.13 |
| 五、利润总额 | 4,952,417,467.84 | 2,556,862,055.54 | 8,707,625,538.18 | 6,412,007,794.73 |
| 减:所得税费用 | 487,135,047.96 | 275,867,350.2 | 990,623,292.4 | 651,772,642.71 |
| 六、净利润 | 4,465,282,419.88 | 2,280,994,705.34 | 7,717,002,245.78 | 5,760,235,152.02 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 4,465,282,419.88 | 2,280,994,705.34 | 7,717,002,245.78 | 5,760,235,152.02 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 4,465,439,428.1 | 2,282,268,233.13 | 7,711,054,811.98 | 5,751,169,537.65 |
| 少数股东损益 | -157,008.22 | -1,273,527.79 | 5,947,433.8 | 9,065,614.37 |
| 扣除非经常损益后的净利润 | 3,729,589,028.7 | 2,172,398,804.54 | 7,413,405,567.05 | 5,589,349,747.69 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.68 | 0.34 | 1.19 | 0.89 |
| (二)稀释每股收益 | 0.68 | 0.34 | 1.18 | 0.89 |
| 八、其他综合收益 | -31,800,666.03 | -13,182,740.49 | 10,995,435.22 | 20,467,114.35 |
| 归属于母公司股东的其他综合收益 | -29,975,797.37 | -12,265,957.44 | 10,992,174.7 | 19,687,815.68 |
| 九、综合收益总额 | 4,433,481,753.85 | 2,267,811,964.85 | 7,727,997,681 | 5,780,702,266.37 |
| 归属于母公司股东的综合收益总额 | 4,435,463,630.73 | 2,270,002,275.69 | 7,722,046,986.68 | 5,770,857,353.33 |
| 归属于少数股东的综合收益总额 | -1,981,876.88 | -2,190,310.84 | 5,950,694.32 | 9,844,913.04 |
| 公告日期 | 2026-08-20 | 2026-04-23 | 2026-03-26 | 2025-10-28 |
| 审计意见(境内) | | | 标准无保留意见 | |